Analyst Reaffirms Buy Rating on Inozyme Pharma with 23 Price Target
On March 12, 2024, analyst Joseph Stringer from Needham reiterated his bullish stance on Inozyme Pharma (NASDAQ: INZY), affirming a ...
© 2024 Stocks Today
Tag: INZY
Popular News
-
Exploring the Rise of AI in Empowering Business and Personal Growth: Trends and Innovations
-
Unlocking the Future: The Rise of Open-Source FPGA Development Tools
-
The Future of Secure Communications: How Quantum-Resistant Encryption is Revolutionizing Wireless Technology
-
The Booming Market of Plant-Based Pharmaceuticals for Neurological Conditions
-
Unlocking Potential: How Recent Acquisitions in the Battery Technology Sector Are Reshaping the Energy Landscape